European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“Big news from EANO2025!
The EORTC CATNON trial has delivered final results that could change the standard of care for patients with IDH-mutant anaplastic astrocytoma. The findings show that adding 12 cycles of temozolomide after radiotherapy can significantly improve overall survival, with a median survival of 12.5 years, compared to 6 years with radiotherapy alone.
Congratulations to Dr Martin J van den Bent for presenting this landmark. A global academic effort showing the power of long-term research in rare cancers.
Read the full press release here.”
More from EORTC.